GPR35; ADRA2C; ADRA2A; DRD4; | |
NPSR1; CXCR1; NMUR2; | |
RECQL; TDP1; PLA2G1B; BLM; APOBEC3G; P4HB; TERT; PKM; PIK3CG; PIK3R1; GLO1; HPGD; PGD; MPO; AKR1B1; HSD17B2; HSD17B10; ALOX15; ALDH1A1; ALOX12; NOX4; USP2; PYGL; APEX1; POLB; | |
ACHE; GAA; | |
DUSP3; | |
BCL2; | |
TOP2A; | |
AKT1; MET; CAMK2B; INSR; CSNK2A1; DAPK1; SYK; NEK2; AXL; FLT3; NEK6; SRC; IGF1R; PTK2; BRAF; AURKB; AURKA; DYRK1A; FLT4; EPHB4; MAP3K8; TEK; PDGFRB; GSK3B; PLK4; CDK1; MAPK1; MAPK14; EGFR; ERBB2; PIM1; NUAK1; ALK; MYLK; KDR; PLK1; PKN1; | |
CA12; CA14; CA5B; CA3; CA7; CA5A; CA1; CA9; CA13; CA4; CA6; CA2; | |
KDM4E; | |
MAOA; ALOX5; XDH; | |
MMP13; MMP3; MMP2; MMP14; MMP9; | |
BACE1; | |
STAT6; HIF1A; NFKB1; TP53; | |
DNMT1; | |
FUT7; | |
ABCC1; ABCB1; ABCG2; | |
SLC22A6; | |
SMAD3; LMNA; MAPT; HBB; THPO; APP; HSPA1A; | |
L3MBTL1; |
Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
---|---|---|---|---|
Aspartic protease | BACE1 | Beta-secretase 1 | P56817 | CHEMBL4822 |
ATP-binding cassette | ABCC1 | Multidrug resistance-associated protein 1 | P33527 | CHEMBL3004 |
ATP-binding cassette | ABCB1 | P-glycoprotein 1 | P08183 | CHEMBL4302 |
ATP-binding cassette | ABCG2 | ATP-binding cassette sub-family G member 2 | Q9UNQ0 | CHEMBL5393 |
Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
Cytochrome P450 family 1 | CYP1A1 | Cytochrome P450 1A1 | P04798 | CHEMBL2231 |
Cytochrome P450 family 19 | CYP19A1 | Cytochrome P450 19A1 | P11511 | CHEMBL1978 |
Cytochrome P450 family 2 | CYP2C19 | Cytochrome P450 2C19 | P33261 | CHEMBL3622 |
Cytochrome P450 family 2 | CYP2C9 | Cytochrome P450 2C9 | P11712 | CHEMBL3397 |
Cytochrome P450 family 2 | CYP2C8 | Cytochrome P450 2C8 | P10632 | CHEMBL3721 |
Cytochrome P450 family 3 | CYP3A4 | Cytochrome P450 3A4 | P08684 | CHEMBL340 |
DNA methyltransferase | DNMT1 | DNA (cytosine-5)-methyltransferase 1 | P26358 | CHEMBL1993 |
Enzyme_unclassified | PYGL | Liver glycogen phosphorylase | P06737 | CHEMBL2568 |
Enzyme_unclassified | APEX1 | DNA-(apurinic or apyrimidinic site) lyase | P27695 | CHEMBL5619 |
Enzyme_unclassified | POLB | DNA polymerase beta | P06746 | CHEMBL2392 |
Enzyme_unclassified | RECQL | ATP-dependent DNA helicase Q1 | P46063 | CHEMBL1293236 |
Enzyme_unclassified | TDP1 | Tyrosyl-DNA phosphodiesterase 1 | Q9NUW8 | CHEMBL1075138 |
Enzyme_unclassified | PLA2G1B | Phospholipase A2 group 1B | P04054 | CHEMBL4426 |
Enzyme_unclassified | BLM | Bloom syndrome protein | P54132 | CHEMBL1293237 |
Enzyme_unclassified | APOBEC3G | DNA dC->dU-editing enzyme APOBEC-3G | Q9HC16 | CHEMBL1741217 |
Enzyme_unclassified | P4HB | Protein disulfide-isomerase | P07237 | CHEMBL5422 |
Enzyme_unclassified | TERT | Telomerase reverse transcriptase | O14746 | CHEMBL2916 |
Enzyme_unclassified | PKM | Pyruvate kinase isozymes M1/M2 | P14618 | CHEMBL1075189 |
Enzyme_unclassified | PIK3CG | PI3-kinase p110-gamma subunit | P48736 | CHEMBL3267 |
Enzyme_unclassified | PIK3R1 | PI3-kinase p85-alpha subunit | P27986 | CHEMBL2506 |
Enzyme_unclassified | GLO1 | Glyoxalase I | Q04760 | CHEMBL2424 |
Enzyme_unclassified | HPGD | 15-hydroxyprostaglandin dehydrogenase [NAD+] | P15428 | CHEMBL1293255 |
Enzyme_unclassified | PGD | 6-phosphogluconate dehydrogenase | P52209 | CHEMBL3404 |
Enzyme_unclassified | MPO | Myeloperoxidase | P05164 | CHEMBL2439 |
Enzyme_unclassified | AKR1B1 | Aldose reductase | P15121 | CHEMBL1900 |
Enzyme_unclassified | HSD17B2 | Estradiol 17-beta-dehydrogenase 2 | P37059 | CHEMBL2789 |
Enzyme_unclassified | HSD17B10 | Endoplasmic reticulum-associated amyloid beta-peptide-binding protein | Q99714 | CHEMBL4159 |
Enzyme_unclassified | ALOX15 | Arachidonate 15-lipoxygenase | P16050 | CHEMBL2903 |
Enzyme_unclassified | ALDH1A1 | Aldehyde dehydrogenase 1A1 | P00352 | CHEMBL3577 |
Enzyme_unclassified | ALOX12 | Arachidonate 12-lipoxygenase | P18054 | CHEMBL3687 |
Enzyme_unclassified | NOX4 | NADPH oxidase 4 | Q9NPH5 | CHEMBL1250375 |
Enzyme_unclassified | USP2 | Ubiquitin carboxyl-terminal hydrolase 2 | O75604 | CHEMBL1293227 |
Hydrolase | ACHE | Acetylcholinesterase | P22303 | CHEMBL220 |
Hydrolase | GAA | Lysosomal alpha-glucosidase | P10253 | CHEMBL2608 |
Isomerase | TOP2A | DNA topoisomerase II alpha | P11388 | CHEMBL1806 |
Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
Lyase | CA14 | Carbonic anhydrase XIV | Q9ULX7 | CHEMBL3510 |
Lyase | CA5B | Carbonic anhydrase VB | Q9Y2D0 | CHEMBL3969 |
Lyase | CA3 | Carbonic anhydrase III | P07451 | CHEMBL2885 |
Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
Lyase | CA5A | Carbonic anhydrase VA | P35218 | CHEMBL4789 |
Lyase | CA1 | Carbonic anhydrase I | P00915 | CHEMBL261 |
Lyase | CA9 | Carbonic anhydrase IX | Q16790 | CHEMBL3594 |
Lyase | CA13 | Carbonic anhydrase XIII | Q8N1Q1 | CHEMBL3912 |
Lyase | CA4 | Carbonic anhydrase IV | P22748 | CHEMBL3729 |
Lyase | CA6 | Carbonic anhydrase VI | P23280 | CHEMBL3025 |
Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
Lysine demethylase | KDM4E | Lysine-specific demethylase 4D-like | B2RXH2 | CHEMBL1293226 |
Metallo protease | MMP14 | Matrix metalloproteinase 14 | P50281 | CHEMBL3869 |
Metallo protease | MMP9 | Matrix metalloproteinase 9 | P14780 | CHEMBL321 |
Metallo protease | MMP13 | Matrix metalloproteinase 13 | P45452 | CHEMBL280 |
Metallo protease | MMP3 | Matrix metalloproteinase 3 | P08254 | CHEMBL283 |
Metallo protease | MMP2 | Matrix metalloproteinase-2 | P08253 | CHEMBL333 |
Methyl-lysine/arginine binding protein | L3MBTL1 | Lethal(3)malignant brain tumor-like protein 1 | Q9Y468 | CHEMBL1287622 |
Miscellaneous ion channel | BCL2 | Apoptosis regulator Bcl-2 | P10415 | CHEMBL4860 |
Oxidoreductase | XDH | Xanthine dehydrogenase | P47989 | CHEMBL1929 |
Oxidoreductase | MAOA | Monoamine oxidase A | P21397 | CHEMBL1951 |
Oxidoreductase | ALOX5 | Arachidonate 5-lipoxygenase | P09917 | CHEMBL215 |
Peptide receptor (family A GPCR) | NPSR1 | Neuropeptide S receptor | Q6W5P4 | CHEMBL5162 |
Peptide receptor (family A GPCR) | CXCR1 | Interleukin-8 receptor A | P25024 | CHEMBL4029 |
Peptide receptor (family A GPCR) | NMUR2 | Neuromedin-U receptor 2 | Q9GZQ4 | CHEMBL1075144 |
Protein Kinase | AKT1 | Serine/threonine-protein kinase AKT | P31749 | CHEMBL4282 |
Protein Kinase | MET | Hepatocyte growth factor receptor | P08581 | CHEMBL3717 |
Protein Kinase | CAMK2B | CaM kinase II beta | Q13554 | CHEMBL4121 |
Protein Kinase | INSR | Insulin receptor | P06213 | CHEMBL1981 |
Protein Kinase | CSNK2A1 | Casein kinase II alpha | P68400 | CHEMBL3629 |
Protein Kinase | DAPK1 | Death-associated protein kinase 1 | P53355 | CHEMBL2558 |
Protein Kinase | SYK | Tyrosine-protein kinase SYK | P43405 | CHEMBL2599 |
Protein Kinase | NEK2 | Serine/threonine-protein kinase NEK2 | P51955 | CHEMBL3835 |
Protein Kinase | AXL | Tyrosine-protein kinase receptor UFO | P30530 | CHEMBL4895 |
Protein Kinase | FLT3 | Tyrosine-protein kinase receptor FLT3 | P36888 | CHEMBL1974 |
Protein Kinase | NEK6 | Serine/threonine-protein kinase NEK6 | Q9HC98 | CHEMBL4309 |
Protein Kinase | SRC | Tyrosine-protein kinase SRC | P12931 | CHEMBL267 |
Protein Kinase | IGF1R | Insulin-like growth factor I receptor | P08069 | CHEMBL1957 |
Protein Kinase | PTK2 | Focal adhesion kinase 1 | Q05397 | CHEMBL2695 |
Protein Kinase | BRAF | Serine/threonine-protein kinase B-raf | P15056 | CHEMBL5145 |
Protein Kinase | AURKB | Serine/threonine-protein kinase Aurora-B | Q96GD4 | CHEMBL2185 |
Protein Kinase | AURKA | Serine/threonine-protein kinase Aurora-A | O14965 | CHEMBL4722 |
Protein Kinase | DYRK1A | Dual-specificity tyrosine-phosphorylation regulated kinase 1A | Q13627 | CHEMBL2292 |
Protein Kinase | FLT4 | Vascular endothelial growth factor receptor 3 | P35916 | CHEMBL1955 |
Protein Kinase | EPHB4 | Ephrin type-B receptor 4 | P54760 | CHEMBL5147 |
Protein Kinase | MAP3K8 | Mitogen-activated protein kinase kinase kinase 8 | P41279 | CHEMBL4899 |
Protein Kinase | TEK | Tyrosine-protein kinase TIE-2 | Q02763 | CHEMBL4128 |
Protein Kinase | PDGFRB | Platelet-derived growth factor receptor beta | P09619 | CHEMBL1913 |
Protein Kinase | GSK3B | Glycogen synthase kinase-3 beta | P49841 | CHEMBL262 |
Protein Kinase | PLK4 | Serine/threonine-protein kinase PLK4 | O00444 | CHEMBL3788 |
Protein Kinase | CDK1 | Cyclin-dependent kinase 1 | P06493 | CHEMBL308 |
Protein Kinase | MAPK1 | MAP kinase ERK2 | P28482 | CHEMBL4040 |
Protein Kinase | MAPK14 | MAP kinase p38 alpha | Q16539 | CHEMBL260 |
Protein Kinase | EGFR | Epidermal growth factor receptor erbB1 | P00533 | CHEMBL203 |
Protein Kinase | ERBB2 | Receptor protein-tyrosine kinase erbB-2 | P04626 | CHEMBL1824 |
Protein Kinase | PIM1 | Serine/threonine-protein kinase PIM1 | P11309 | CHEMBL2147 |
Protein Kinase | NUAK1 | NUAK family SNF1-like kinase 1 | O60285 | CHEMBL5784 |
Protein Kinase | ALK | ALK tyrosine kinase receptor | Q9UM73 | CHEMBL4247 |
Protein Kinase | MYLK | Myosin light chain kinase, smooth muscle | Q15746 | CHEMBL2428 |
Protein Kinase | KDR | Vascular endothelial growth factor receptor 2 | P35968 | CHEMBL279 |
Protein Kinase | PLK1 | Serine/threonine-protein kinase PLK1 | P53350 | CHEMBL3024 |
Protein Kinase | PKN1 | Protein kinase N1 | Q16512 | CHEMBL3384 |
Protein Phosphatase | DUSP3 | Dual specificity protein phosphatase 3 | P51452 | CHEMBL2635 |
SLC superfamily of solute carriers | SLC22A6 | Solute carrier family 22 member 6 | Q4U2R8 | CHEMBL1641347 |
Small molecule receptor (family A GPCR) | GPR35 | G-protein coupled receptor 35 | Q9HC97 | CHEMBL1293267 |
Small molecule receptor (family A GPCR) | ADRA2C | Alpha-2c adrenergic receptor | P18825 | CHEMBL1916 |
Small molecule receptor (family A GPCR) | ADRA2A | Alpha-2a adrenergic receptor | P08913 | CHEMBL1867 |
Small molecule receptor (family A GPCR) | DRD4 | Dopamine D4 receptor | P21917 | CHEMBL219 |
Transcription Factor | STAT6 | Signal transducer and activator of transcription 6 | P42226 | CHEMBL5401 |
Transcription Factor | HIF1A | Hypoxia-inducible factor 1 alpha | Q16665 | CHEMBL4261 |
Transcription Factor | NFKB1 | Nuclear factor NF-kappa-B p105 subunit | P19838 | CHEMBL3251 |
Transcription Factor | TP53 | Cellular tumor antigen p53 | P04637 | CHEMBL4096 |
Transferase | FUT7 | Alpha-(1,3)-fucosyltransferase 7 | Q11130 | CHEMBL3596077 |
Unclassified | SMAD3 | Mothers against decapentaplegic homolog 3 | P84022 | CHEMBL1293258 |
Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
Unclassified | MAPT | Microtubule-associated protein tau | P10636 | CHEMBL1293224 |
Unclassified | HBB | Hemoglobin beta chain | P68871 | CHEMBL4331 |
Unclassified | THPO | Thrombopoietin | P40225 | CHEMBL1293256 |
Unclassified | APP | Beta amyloid A4 protein | P05067 | CHEMBL2487 |
Unclassified | HSPA1A | Heat shock 70 kDa protein 1 | P0DMV8 | CHEMBL5460 |
GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|---|
BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 1.154E-11 | 1.469E-09 | CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C8, CYP2C9 |
BP | GO:0009987; cellular process | GO:0051897; positive regulation of protein kinase B signaling | 1.388E-11 | 1.747E-09 | AXL, EGFR, ERBB2, INSR, MET, NOX4, PDGFRB, PIK3CG, PIK3R1, PTK2, SRC, TEK, THPO |
MF | GO:0005488; binding | GO:0005506; iron ion binding | 2.664E-11 | 3.241E-09 | ALOX12, ALOX15, ALOX5, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C8, CYP2C9, CYP3A4, HBB, XDH |
MF | GO:0005488; binding | GO:0020037; heme binding | 2.974E-11 | 3.578E-09 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C8, CYP2C9, CYP3A4, HBB, MPO, NOX4, SRC |
MF | Unclassified; | GO:0004716; signal transducer, downstream of receptor, with protein tyrosine kinase activity | 1.143E-09 | 1.168E-07 | EGFR, ERBB2, INSR, KDR, SYK |
MF | GO:0005488; binding | GO:0008270; zinc ion binding | 1.314E-09 | 1.331E-07 | APOBEC3G, BLM, CA1, CA12, CA13, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9, DNMT1, GLO1, L3MBTL1, MMP13, MMP14, MMP2, MMP3, MMP9, SMAD3, TP53 |
MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 1.515E-09 | 1.486E-07 | CYP1A2, CYP2C8, CYP2C9, CYP3A4 |
BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 2.816E-09 | 2.610E-07 | CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C8, CYP2C9 |
MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 5.185E-09 | 4.590E-07 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C8, CYP3A4 |
BP | GO:0050896; response to stimulus | GO:0042738; exogenous drug catabolic process | 7.075E-09 | 6.162E-07 | CYP1A2, CYP2C19, CYP2C8, CYP2C9, CYP3A4 |
BP | GO:0008152; metabolic process | GO:0038083; peptidyl-tyrosine autophosphorylation | 1.719E-08 | 1.462E-06 | EGFR, IGF1R, INSR, KDR, PTK2, SRC, SYK |
BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 2.250E-08 | 1.877E-06 | CYP1A2, CYP2C19, CYP2C9, CYP3A4 |
BP | GO:0009987; cellular process | GO:0030168; platelet activation | 3.227E-08 | 2.603E-06 | ADRA2A, ADRA2C, AKT1, AXL, MAPK1, PIK3CG, PIK3R1, SRC, SYK |
BP | GO:0009987; cellular process | GO:0070374; positive regulation of ERK1 and ERK2 cascade | 4.917E-08 | 3.879E-06 | ALOX15, APP, BRAF, EGFR, FLT4, KDR, NOX4, PDGFRB, SRC, TEK, THPO |
CC | GO:0044464; cell part | GO:0005829; cytosol | 7.920E-08 | 5.967E-06 | AKR1B1, AKT1, ALDH1A1, ALOX12, ALOX15, ALOX5, APOBEC3G, APP, AURKA, AURKB, BCL2, BLM, BRAF, CA1, CA13, CA2, CA3, CA7, CAMK2B, CDK1, CSNK2A1, DUSP3, EPHB4, ERBB2, FLT3, GLO1, GSK3B, HBB, HIF1A, HPGD, HSPA1A, LMNA, MAP3K8, MAPK1, MAPK14, MAPT, MMP14, MYLK, NEK2, NEK6, NFKB1, PGD, PIK3CG, PIK3R1, PIM1, PKM, PKN1, PLA2G1B, PLK1, PLK4, PTK2, PYGL, SMAD3, SRC, STAT6, SYK, TP53, XDH |
MF | GO:0005488; binding | GO:0042803; protein homodimerization activity | 1.233E-07 | 9.013E-06 | ABCG2, ACHE, ADRA2A, ADRA2C, AKT1, APOBEC3G, BCL2, BLM, CAMK2B, FLT3, FLT4, HPGD, MAPT, NFKB1, PYGL, SLC22A6, SMAD3, TERT, TOP2A, XDH |
BP | GO:0009987; cellular process | GO:1901796; regulation of signal transduction by p53 class mediator | 1.746E-07 | 1.238E-05 | AKT1, AURKA, AURKB, BLM, CSNK2A1, DYRK1A, L3MBTL1, MAPK14, NUAK1, TP53 |
BP | Unclassified; | GO:0032846; positive regulation of homeostatic process | 1.983E-07 | 1.402E-05 | AURKB, CA2, CA7, EGFR, HIF1A, MAPK1, MAPK14, NEK2, NPSR1, PLA2G1B, SYK |
MF | GO:0003824; catalytic activity | GO:0004712; protein serine/threonine/tyrosine kinase activity | 2.443E-07 | 1.694E-05 | AKT1, AURKA, AURKB, DYRK1A, MAPK1, MAPK14 |
CC | GO:0016020; membrane | GO:0016323; basolateral plasma membrane | 2.919E-07 | 1.986E-05 | ABCC1, ADRA2A, CA2, CA4, CA9, EGFR, ERBB2, HPGD, SLC22A6, TEK |
BP | GO:0065007; biological regulation | GO:0000187; activation of MAPK activity | 3.112E-07 | 2.110E-05 | ALK, CDK1, DRD4, INSR, MAPK1, MAPK14, PKN1, PLA2G1B, SYK |
BP | GO:0009987; cellular process | GO:0071456; cellular response to hypoxia | 3.120E-07 | 2.110E-05 | AKT1, BCL2, HIF1A, LMNA, P4HB, SRC, TERT, TP53 |
BP | Unclassified; | GO:0032844; regulation of homeostatic process | 3.229E-07 | 2.177E-05 | ADRA2A, AURKB, BCL2, CA2, CA7, EGFR, HIF1A, KDR, MAPK1, MAPK14, NEK2, NPSR1, PLA2G1B, SRC, SYK |
BP | GO:0009987; cellular process | GO:0048010; vascular endothelial growth factor receptor signaling pathway | 3.535E-07 | 2.361E-05 | AXL, FLT4, KDR, MAPK14, PIK3R1, PTK2, SRC |
MF | GO:0005488; binding | GO:0046982; protein heterodimerization activity | 5.728E-07 | 3.658E-05 | ADRA2A, ADRA2C, AURKA, AXL, BCL2, BRAF, EGFR, ERBB2, HIF1A, NFKB1, P4HB, PIK3R1, SMAD3, TOP2A, TP53 |
BP | GO:0008152; metabolic process | GO:0070989; oxidative demethylation | 7.210E-07 | 4.511E-05 | CYP1A2, CYP2C8, CYP2C9, CYP3A4 |
MF | GO:0005488; binding | GO:0043548; phosphatidylinositol 3-kinase binding | 9.735E-07 | 5.855E-05 | AXL, IGF1R, INSR, PDGFRB, PIK3R1 |
BP | GO:0008152; metabolic process | GO:0043552; positive regulation of phosphatidylinositol 3-kinase activity | 1.162E-06 | 6.731E-05 | FLT3, PDGFRB, PTK2, SRC, TEK |
BP | GO:0009987; cellular process | GO:0071276; cellular response to cadmium ion | 1.379E-06 | 7.819E-05 | AKT1, CYP1A2, EGFR, MAPK1, MMP9 |
MF | GO:0005488; binding | GO:0019838; growth factor binding | 1.716E-06 | 9.626E-05 | EGFR, ERBB2, FLT4, IGF1R, INSR, KDR, PDGFRB, TEK |
BP | GO:0009987; cellular process | GO:0038084; vascular endothelial growth factor signaling pathway | 1.959E-06 | 1.080E-04 | FLT3, FLT4, KDR, PDGFRB |
BP | GO:0065007; biological regulation | GO:0032148; activation of protein kinase B activity | 2.224E-06 | 1.208E-04 | ADRA2A, ADRA2C, AKT1, INSR, SRC |
BP | GO:0009987; cellular process | GO:0070301; cellular response to hydrogen peroxide | 2.345E-06 | 1.261E-04 | AKR1B1, APEX1, AXL, CDK1, CYP1B1, STAT6 |
MF | GO:0003824; catalytic activity | GO:0101020; estrogen 16-alpha-hydroxylase activity | 2.436E-06 | 1.297E-04 | CYP1A1, CYP2C8, CYP3A4 |
MF | Unclassified; | GO:0032403; protein complex binding | 2.543E-06 | 1.350E-04 | ACHE, ADRA2A, APEX1, EGFR, FLT3, IGF1R, INSR, KDR, MMP13, MMP14, MMP9, P4HB, PIK3R1, PKM, PLK1, SMAD3, SRC, SYK |
BP | GO:0008152; metabolic process | GO:0019372; lipoxygenase pathway | 2.600E-06 | 1.374E-04 | ALOX12, ALOX15, ALOX5, HPGD |
BP | GO:0040011; locomotion | GO:0014911; positive regulation of smooth muscle cell migration | 2.983E-06 | 1.554E-04 | BCL2, NOX4, PDGFRB, SRC, TERT |
MF | GO:0003824; catalytic activity | GO:0046934; phosphatidylinositol-4,5-bisphosphate 3-kinase activity | 3.740E-06 | 1.885E-04 | EGFR, ERBB2, MET, PDGFRB, PIK3CG, PIK3R1 |
BP | GO:0065007; biological regulation | GO:0031647; regulation of protein stability | 4.119E-06 | 2.048E-04 | AURKA, BCL2, HSPA1A, MAPK1, PIK3R1, PLK1, SMAD3, SRC, TERT, USP2 |
BP | GO:0008152; metabolic process | GO:0002933; lipid hydroxylation | 4.849E-06 | 2.376E-04 | CYP1A1, CYP2C8, CYP3A4 |
BP | Unclassified; | GO:0044236; multicellular organism metabolic process | 4.899E-06 | 2.382E-04 | HIF1A, MMP13, MMP14, MMP2, MMP3, MMP9, PLA2G1B |
BP | GO:0008152; metabolic process | GO:0045429; positive regulation of nitric oxide biosynthetic process | 5.782E-06 | 2.737E-04 | AKT1, EGFR, HBB, INSR, SMAD3 |
BP | Unclassified; | GO:0044243; multicellular organismal catabolic process | 6.760E-06 | 3.152E-04 | MMP13, MMP14, MMP2, MMP3, MMP9, PLA2G1B |
BP | GO:0009987; cellular process | GO:0043065; positive regulation of apoptotic process | 6.821E-06 | 3.173E-04 | AKT1, BCL2, CYP1B1, DAPK1, GSK3B, HPGD, MAPT, MMP9, NOX4, PDGFRB, SMAD3, SRC, TOP2A, TP53, XDH |
BP | GO:0051179; localization | GO:0046326; positive regulation of glucose import | 7.353E-06 | 3.357E-04 | AKT1, INSR, MAPK14, PIK3R1, TERT |
BP | GO:0009987; cellular process | GO:0070507; regulation of microtubule cytoskeleton organization | 7.689E-06 | 3.495E-04 | AURKA, GSK3B, HSPA1A, MAPT, MET, NEK2, PLK1, PLK4 |
BP | GO:0050896; response to stimulus | GO:0055093; response to hyperoxia | 8.342E-06 | 3.738E-04 | CYP1A1, PDGFRB, POLB, TP53 |
MF | GO:0060089; molecular transducer activity | GO:0005021; vascular endothelial growth factor-activated receptor activity | 8.446E-06 | 3.769E-04 | FLT3, FLT4, KDR |
MF | GO:0005215; transporter activity | GO:0008559; xenobiotic transmembrane transporting ATPase activity | 8.446E-06 | 3.769E-04 | ABCB1, ABCC1, ABCG2 |
BP | GO:0008283; cell proliferation | GO:1904707; positive regulation of vascular smooth muscle cell proliferation | 1.015E-05 | 4.452E-04 | HPGD, MMP2, MMP9, TERT |
BP | GO:0008152; metabolic process | GO:1902895; positive regulation of pri-miRNA transcription from RNA polymerase II promoter | 1.015E-05 | 4.452E-04 | HIF1A, SMAD3, TERT, TP53 |
BP | GO:0023052; signaling | GO:0050806; positive regulation of synaptic transmission | 1.174E-05 | 5.022E-04 | APP, BRAF, CA2, CA7, DRD4, EGFR, MAPK1 |
MF | GO:0005488; binding | GO:0051379; epinephrine binding | 1.345E-05 | 5.655E-04 | ADRA2A, ADRA2C, DRD4 |
CC | GO:0043226; organelle | GO:0005654; nucleoplasm | 1.491E-05 | 6.195E-04 | AKR1B1, AKT1, ALOX5, APEX1, AURKA, AURKB, BCL2, BLM, CAMK2B, CDK1, CSNK2A1, DNMT1, DUSP3, DYRK1A, GSK3B, HIF1A, HPGD, HSPA1A, L3MBTL1, LMNA, MAPK1, MAPK14, NEK2, NEK6, NFKB1, NUAK1, PIM1, PKN1, PLK1, POLB, RECQL, SMAD3, SRC, STAT6, TERT, TOP2A, TP53, USP2 |
BP | GO:0008152; metabolic process | GO:0031324; negative regulation of cellular metabolic process | 1.514E-05 | 6.280E-04 | ADRA2A, AKT1, APEX1, APP, AURKB, BCL2, BLM, CDK1, CSNK2A1, DAPK1, DNMT1, DRD4, DUSP3, DYRK1A, GSK3B, HIF1A, HSPA1A, IGF1R, L3MBTL1, MAPK14, MAPT, MET, MMP3, MMP9, NFKB1, PIK3CG, PKN1, PLK1, SMAD3, SRC, STAT6, TERT, TP53, USP2, XDH |
BP | Unclassified; | GO:0044259; multicellular organismal macromolecule metabolic process | 1.746E-05 | 7.081E-04 | HIF1A, MMP13, MMP14, MMP2, MMP3, MMP9 |
CC | GO:0044464; cell part | GO:0005739; mitochondrion | 1.776E-05 | 7.186E-04 | AKT1, APEX1, BCL2, BRAF, CA5A, CA5B, CDK1, CYP1A1, CYP1B1, GSK3B, HSD17B10, HSPA1A, MAOA, MAPK1, MAPK14, MMP2, MPO, NFKB1, NOX4, PKM, SRC, TP53 |
BP | GO:0032501; multicellular organismal process | GO:0048143; astrocyte activation | 2.008E-05 | 7.995E-04 | APP, EGFR, MAPT |
BP | GO:0009987; cellular process | GO:0000733; DNA strand renaturation | 2.008E-05 | 7.995E-04 | BLM, RECQL, TP53 |
CC | GO:0043226; organelle | GO:0005876; spindle microtubule | 2.084E-05 | 8.252E-04 | AURKA, AURKB, CDK1, PLK1, POLB |
BP | GO:0008152; metabolic process | GO:0045740; positive regulation of DNA replication | 2.501E-05 | 9.709E-04 | CDK1, EGFR, IGF1R, INSR, PLA2G1B |
MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 1.036E-24 | 2.819E-21 | CA1, CA12, CA13, CA14, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9 |
MF | GO:0005488; binding | GO:0051721; protein phosphatase 2A binding | 2.758E-05 | 1.063E-03 | AKT1, BCL2, MAPT, TP53 |
BP | GO:0051179; localization | GO:2001225; regulation of chloride transport | 2.856E-05 | 1.095E-03 | ABCB1, CA2, CA7 |
BP | GO:0051179; localization | GO:0042908; xenobiotic transport | 2.856E-05 | 1.095E-03 | ABCB1, ABCC1, ABCG2 |
BP | GO:0009987; cellular process | GO:2001243; negative regulation of intrinsic apoptotic signaling pathway | 3.082E-05 | 1.175E-03 | AKT1, BCL2, HIF1A, HSPA1A, MMP9, SRC |
BP | GO:0065007; biological regulation | GO:0051090; regulation of DNA binding transcription factor activity | 3.565E-05 | 1.345E-03 | AKT1, ALK, APP, CYP1B1, HSPA1A, MAPK1, MAPK14, NFKB1, PIM1, PLA2G1B, SYK |
MF | Unclassified; | GO:0099600; transmembrane receptor activity | 3.665E-05 | 1.373E-03 | ADRA2A, ADRA2C, ALK, AXL, CXCR1, DRD4, EGFR, EPHB4, ERBB2, FLT3, FLT4, GPR35, HPGD, IGF1R, INSR, KDR, MET, NMUR2, NPSR1, PDGFRB, TEK |
BP | GO:0009987; cellular process | GO:0010389; regulation of G2/M transition of mitotic cell cycle | 3.756E-05 | 1.403E-03 | APP, AURKA, AURKB, BLM, CDK1, NEK2, PLK1, PLK4 |
CC | GO:0032991; macromolecular complex | GO:0043235; receptor complex | 3.820E-05 | 1.422E-03 | ABCG2, ADRA2A, APP, EGFR, ERBB2, FLT4, IGF1R, INSR, SMAD3, SYK |
BP | GO:0008152; metabolic process | GO:0046854; phosphatidylinositol phosphorylation | 3.893E-05 | 1.447E-03 | EGFR, ERBB2, MET, PDGFRB, PIK3CG, PIK3R1 |
BP | GO:0065007; biological regulation | GO:0043006; activation of phospholipase A2 activity by calcium-mediated signaling | 3.957E-05 | 1.449E-03 | EGFR, NMUR2 |
BP | GO:0009987; cellular process | GO:0006286; base-excision repair, base-free sugar-phosphate removal | 3.957E-05 | 1.449E-03 | APEX1, POLB |
BP | GO:0008152; metabolic process | GO:2001303; lipoxin A4 biosynthetic process | 3.957E-05 | 1.449E-03 | ALOX12, ALOX15 |
MF | GO:0005488; binding | GO:0043560; insulin receptor substrate binding | 3.909E-05 | 1.449E-03 | IGF1R, INSR, PIK3R1 |
MF | GO:0003824; catalytic activity | GO:0047977; hepoxilin-epoxide hydrolase activity | 3.957E-05 | 1.449E-03 | ALOX12, ALOX15 |
CC | GO:0043226; organelle | GO:0051233; spindle midzone | 4.177E-05 | 1.521E-03 | APP, AURKA, AURKB, PLK1 |
BP | GO:0032501; multicellular organismal process | GO:0003007; heart morphogenesis | 4.750E-05 | 1.701E-03 | EPHB4, GAA, INSR, PTK2 |
MF | GO:0005488; binding | GO:0051879; Hsp90 protein binding | 4.750E-05 | 1.701E-03 | CSNK2A1, HIF1A, KDR, MAPT |
BP | GO:0065007; biological regulation | GO:0060249; anatomical structure homeostasis | 5.038E-05 | 1.799E-03 | AKR1B1, APEX1, BCL2, BLM, GAA, HIF1A, NOX4, SRC, TERT |
BP | GO:0008152; metabolic process | GO:0019318; hexose metabolic process | 5.335E-05 | 1.892E-03 | AKR1B1, AKT1, ALDH1A1, FUT7, GAA, MAPK14, PKM |
BP | Unclassified; | GO:0006461; protein complex assembly | 5.442E-05 | 1.917E-03 | ACHE, BLM, BRAF, CDK1, GSK3B, HBB, HSD17B10, HSPA1A, IGF1R, INSR, MAPT, PKM, PTK2, SLC22A6, SMAD3, SRC, TEK, TERT, TP53 |
BP | GO:0002376; immune system process | GO:0043312; neutrophil degranulation | 5.505E-05 | 1.930E-03 | ALOX5, CXCR1, GAA, HBB, HSPA1A, MAPK1, MAPK14, MMP9, MPO, NFKB1, PKM, PYGL |
BP | GO:0008152; metabolic process | GO:0030574; collagen catabolic process | 5.648E-05 | 1.974E-03 | MMP13, MMP14, MMP2, MMP3, MMP9 |
BP | GO:0009987; cellular process | GO:2001240; negative regulation of extrinsic apoptotic signaling pathway in absence of ligand | 6.067E-05 | 2.100E-03 | AKT1, BCL2, HSPA1A, TERT |
BP | GO:0009987; cellular process | GO:0014068; positive regulation of phosphatidylinositol 3-kinase signaling | 6.080E-05 | 2.101E-03 | FLT3, KDR, PDGFRB, PTK2, TEK |
BP | GO:0065007; biological regulation | GO:0042593; glucose homeostasis | 6.805E-05 | 2.335E-03 | ADRA2A, AKT1, HIF1A, INSR, NOX4, PIK3R1, PYGL |
BP | GO:0008152; metabolic process | GO:0045913; positive regulation of carbohydrate metabolic process | 7.021E-05 | 2.400E-03 | AKT1, HIF1A, INSR, NFKB1, SRC |
BP | GO:0051179; localization | GO:1905477; positive regulation of protein localization to membrane | 7.398E-05 | 2.509E-03 | AKT1, BCL2, EGFR, ERBB2, PIK3R1, TP53 |
BP | GO:0032502; developmental process | GO:0002009; morphogenesis of an epithelium | 7.671E-05 | 2.588E-03 | BCL2, CA2, CA9, EGFR, HIF1A, MET, MMP14, SMAD3, SRC |
MF | GO:0005488; binding | GO:0002039; p53 binding | 8.070E-05 | 2.708E-03 | BLM, GSK3B, HIF1A, NUAK1, TP53 |
BP | GO:0050896; response to stimulus | GO:0034405; response to fluid shear stress | 8.514E-05 | 2.826E-03 | AKT1, CA2, PDGFRB, SRC |
BP | GO:0009987; cellular process | GO:0031334; positive regulation of protein complex assembly | 9.227E-05 | 3.049E-03 | ALOX15, GSK3B, HSPA1A, MAPT, MET, MMP3, SRC, TP53 |
BP | GO:0050896; response to stimulus | GO:0043627; response to estrogen | 9.865E-05 | 3.240E-03 | CA2, MAPK1, MMP14, PDGFRB, TEK |
BP | GO:0009987; cellular process | GO:0038128; ERBB2 signaling pathway | 1.050E-04 | 3.418E-03 | EGFR, ERBB2, PIK3R1, SRC |
BP | GO:0032501; multicellular organismal process | GO:0045780; positive regulation of bone resorption | 1.058E-04 | 3.434E-03 | CA2, EGFR, SYK |
BP | GO:0022610; biological adhesion | GO:0033628; regulation of cell adhesion mediated by integrin | 1.161E-04 | 3.745E-03 | CYP1B1, PIK3CG, PTK2, SYK |
BP | GO:0051179; localization | GO:0099039; sphingolipid translocation | 1.182E-04 | 3.774E-03 | ABCB1, ABCC1 |
BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 1.182E-04 | 3.774E-03 | CA2, CA7 |
MF | GO:0003824; catalytic activity | GO:0070576; vitamin D 24-hydroxylase activity | 1.182E-04 | 3.774E-03 | CYP1A1, CYP3A4 |
MF | GO:0003824; catalytic activity | GO:0004052; arachidonate 12-lipoxygenase activity | 1.182E-04 | 3.774E-03 | ALOX12, ALOX15 |
MF | GO:0060089; molecular transducer activity | GO:0004938; alpha2-adrenergic receptor activity | 1.182E-04 | 3.774E-03 | ADRA2A, ADRA2C |
MF | GO:0003824; catalytic activity | GO:0051120; hepoxilin A3 synthase activity | 1.182E-04 | 3.774E-03 | ALOX12, ALOX15 |
BP | GO:0065007; biological regulation | GO:0010952; positive regulation of peptidase activity | 1.197E-04 | 3.795E-03 | APP, DAPK1, MAPK14, MAPT, MMP14, SMAD3, XDH |
BP | GO:0009987; cellular process | GO:2000811; negative regulation of anoikis | 1.296E-04 | 4.050E-03 | BCL2, PTK2, SRC |
BP | GO:0032501; multicellular organismal process | GO:0048546; digestive tract morphogenesis | 1.296E-04 | 4.050E-03 | BCL2, EGFR, HIF1A |
BP | GO:0009987; cellular process | GO:1900034; regulation of cellular response to heat | 1.352E-04 | 4.206E-03 | CAMK2B, GSK3B, HSPA1A, MAPK1, MAPT |
BP | GO:0051179; localization | GO:0043270; positive regulation of ion transport | 1.361E-04 | 4.220E-03 | ABCB1, ADRA2A, AKT1, DRD4, MYLK, NPSR1, PDGFRB, PLA2G1B |
BP | GO:0009987; cellular process | GO:0022617; extracellular matrix disassembly | 1.436E-04 | 4.436E-03 | MMP13, MMP14, MMP2, MMP3, MMP9 |
BP | GO:0065007; biological regulation | GO:1904355; positive regulation of telomere capping | 1.567E-04 | 4.743E-03 | AURKB, MAPK1, NEK2 |
MF | GO:0003824; catalytic activity | GO:0008392; arachidonic acid epoxygenase activity | 1.567E-04 | 4.743E-03 | CYP2C19, CYP2C8, CYP2C9 |
BP | GO:0008152; metabolic process | GO:0032436; positive regulation of proteasomal ubiquitin-dependent protein catabolic process | 1.617E-04 | 4.862E-03 | AKT1, AURKA, GSK3B, HSPA1A, PLK1 |
BP | GO:0032501; multicellular organismal process | GO:0043536; positive regulation of blood vessel endothelial cell migration | 1.691E-04 | 5.052E-03 | AKT1, HIF1A, KDR, MAPK14 |
BP | GO:0009987; cellular process | GO:0007077; mitotic nuclear envelope disassembly | 1.691E-04 | 5.052E-03 | CDK1, LMNA, NEK6, PLK1 |
BP | GO:0009987; cellular process | GO:0090199; regulation of release of cytochrome c from mitochondria | 1.847E-04 | 5.436E-03 | AKT1, LMNA, MMP9, TP53 |
BP | GO:0008152; metabolic process | GO:0051000; positive regulation of nitric-oxide synthase activity | 1.872E-04 | 5.478E-03 | AKT1, HIF1A, TERT |
BP | GO:0008152; metabolic process | GO:0032928; regulation of superoxide anion generation | 1.872E-04 | 5.478E-03 | EGFR, MAPT, SYK |
BP | GO:0008152; metabolic process | GO:0008610; lipid biosynthetic process | 2.001E-04 | 5.804E-03 | ACHE, AKR1B1, ALOX12, ALOX15, CSNK2A1, CYP19A1, CYP1A1, CYP3A4, HSD17B2, PIK3CG, PIK3R1, PLA2G1B |
BP | GO:0008283; cell proliferation | GO:0001938; positive regulation of endothelial cell proliferation | 2.143E-04 | 6.148E-03 | AKT1, FLT4, HIF1A, KDR, TEK |
BP | GO:0065007; biological regulation | GO:0035625; epidermal growth factor-activated receptor transactivation by G-protein coupled receptor signaling pathway | 2.354E-04 | 6.649E-03 | ADRA2A, ADRA2C |
BP | GO:0009987; cellular process | GO:0032811; negative regulation of epinephrine secretion | 2.354E-04 | 6.649E-03 | ADRA2A, ADRA2C |
BP | GO:0008152; metabolic process | GO:0018894; dibenzo-p-dioxin metabolic process | 2.354E-04 | 6.649E-03 | CYP1A1, CYP1A2 |
MF | GO:0005488; binding | GO:0051425; PTB domain binding | 2.354E-04 | 6.649E-03 | APP, INSR |
BP | GO:0050896; response to stimulus | GO:0009612; response to mechanical stimulus | 2.416E-04 | 6.779E-03 | AKT1, EGFR, MAPK14, MMP14, MPO, NFKB1, SRC |
CC | GO:0044421; extracellular region part | GO:0070062; extracellular exosome | 2.695E-04 | 7.383E-03 | ABCB1, ABCC1, AKR1B1, ALDH1A1, ALK, ALOX12, APP, AXL, CA1, CA2, CA4, CA6, CDK1, DUSP3, EPHB4, GAA, GLO1, HBB, HPGD, HSPA1A, INSR, MAPK1, MAPK14, MMP9, MPO, MYLK, P4HB, PDGFRB, PGD, PKM, PYGL, SLC22A6, SRC |
BP | GO:0050896; response to stimulus | GO:0071320; cellular response to cAMP | 2.787E-04 | 7.585E-03 | APEX1, APP, NOX4, PIK3CG |
MF | GO:0003824; catalytic activity | GO:0004715; non-membrane spanning protein tyrosine kinase activity | 3.009E-04 | 8.140E-03 | DYRK1A, PTK2, SRC, SYK |
MF | GO:0005488; binding | GO:0003682; chromatin binding | 3.369E-04 | 9.035E-03 | APEX1, CDK1, DNMT1, EGFR, L3MBTL1, MPO, NFKB1, PKN1, SMAD3, TOP2A, TP53 |
BP | GO:0009987; cellular process | GO:0051983; regulation of chromosome segregation | 3.408E-04 | 9.116E-03 | AURKB, CSNK2A1, NEK2, NEK6, PLK1 |
BP | GO:0009987; cellular process | GO:0051262; protein tetramerization | 3.435E-04 | 9.176E-03 | ACHE, HSD17B10, IGF1R, INSR, PKM, TP53 |
BP | GO:0008152; metabolic process | GO:0050995; negative regulation of lipid catabolic process | 3.468E-04 | 9.253E-03 | ADRA2A, AKT1, PIK3CG |
BP | Unclassified; | GO:2000021; regulation of ion homeostasis | 3.573E-04 | 9.476E-03 | BCL2, CA2, CA7, KDR, NPSR1, PLA2G1B, SRC |
BP | GO:0032501; multicellular organismal process | GO:0003014; renal system process | 3.577E-04 | 9.476E-03 | AKR1B1, BCL2, HBB, PKN1, SLC22A6 |
BP | GO:0050896; response to stimulus | GO:0010332; response to gamma radiation | 3.753E-04 | 9.823E-03 | BCL2, NOX4, POLB, TP53 |
MF | GO:0005488; binding | GO:0043621; protein self-association | 3.753E-04 | 9.823E-03 | ACHE, DYRK1A, FLT3, TP53 |
BP | GO:0050896; response to stimulus | GO:0032496; response to lipopolysaccharide | 3.800E-04 | 9.934E-03 | AXL, CYP1A1, CYP1A2, HPGD, MAPK14, MPO, NFKB1, SRC |
MF | GO:0005488; binding | GO:0005524; ATP binding | 1.127E-22 | 1.753E-19 | ABCB1, ABCC1, ABCG2, AKT1, ALK, AURKA, AURKB, AXL, BLM, BRAF, CAMK2B, CDK1, CSNK2A1, DAPK1, DYRK1A, EGFR, EPHB4, ERBB2, FLT3, FLT4, GSK3B, HSPA1A, IGF1R, INSR, KDR, MAP3K8, MAPK1, MAPK14, MET, MYLK, NEK2, NEK6, NUAK1, PDGFRB, PIK3CG, PIM1, PKM, PKN1, PLK1, PLK4, PTK2, PYGL, RECQL, SRC, SYK, TEK, TOP2A, TP53 |
BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 5.812E-19 | 2.812E-16 | CA1, CA12, CA13, CA14, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9, HBB |
BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 2.117E-16 | 5.692E-14 | CA1, CA12, CA13, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9 |
MF | GO:0005488; binding | GO:0019825; oxygen binding | 1.838E-13 | 2.921E-11 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C8, CYP2C9, CYP3A4, HBB, NOX4 |
Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|
hsa00910 | Nitrogen metabolism_Homo sapiens_hsa00910 | 9.187E-24 | 1.801E-21 | CA12; CA1; CA3; CA5B; CA2; CA5A; CA4; CA7; CA6; CA9; CA14; CA13 |
hsa05205 | Proteoglycans in cancer_Homo sapiens_hsa05205 | 3.627E-16 | 3.555E-14 | CAMK2B; SRC; MMP2; BRAF; PIK3R1; MAPK14; HIF1A; MMP9; PTK2; EGFR; PIK3CG; IGF1R; ERBB2; KDR; AKT1; MAPK1; TP53; MET |
hsa04510 | Focal adhesion_Homo sapiens_hsa04510 | 6.086E-15 | 3.140E-13 | PDGFRB; GSK3B; SRC; FLT4; BRAF; PIK3R1; PTK2; EGFR; PIK3CG; MYLK; IGF1R; ERBB2; KDR; BCL2; AKT1; MAPK1; MET |
hsa05200 | Pathways in cancer_Homo sapiens_hsa05200 | 3.469E-14 | 1.133E-12 | PDGFRB; GSK3B; SMAD3; FLT3; DAPK1; MMP2; BRAF; PIK3R1; HIF1A; MMP9; EGFR; NFKB1; PIK3CG; PTK2; IGF1R; ERBB2; BCL2; AKT1; MAPK1; MET; TP53 |
hsa05215 | Prostate cancer_Homo sapiens_hsa05215 | 8.010E-15 | 3.140E-13 | PDGFRB; GSK3B; BRAF; PIK3R1; EGFR; NFKB1; PIK3CG; IGF1R; ERBB2; BCL2; AKT1; MAPK1; TP53 |
hsa05230 | Central carbon metabolism in cancer_Homo sapiens_hsa05230 | 6.901E-15 | 3.140E-13 | PDGFRB; PKM; FLT3; ERBB2; AKT1; MAPK1; PIK3R1; TP53; MET; HIF1A; EGFR; PIK3CG |
hsa04151 | PI3K-Akt signaling pathway_Homo sapiens_hsa04151 | 2.558E-13 | 6.268E-12 | PDGFRB; GSK3B; SYK; INSR; FLT4; PIK3R1; PTK2; EGFR; NFKB1; PIK3CG; IGF1R; KDR; BCL2; AKT1; MAPK1; TEK; PKN1; TP53; MET |
hsa04066 | HIF-1 signaling pathway_Homo sapiens_hsa04066 | 5.679E-14 | 1.590E-12 | CAMK2B; INSR; PIK3R1; HIF1A; EGFR; NFKB1; PIK3CG; IGF1R; ERBB2; BCL2; AKT1; MAPK1; TEK |
hsa04015 | Rap1 signaling pathway_Homo sapiens_hsa04015 | 3.088E-12 | 6.053E-11 | PDGFRB; SRC; INSR; FLT4; BRAF; PIK3R1; MAPK14; EGFR; PIK3CG; IGF1R; KDR; AKT1; MAPK1; TEK; MET |
hsa05214 | Glioma_Homo sapiens_hsa05214 | 6.617E-12 | 1.081E-10 | PDGFRB; CAMK2B; AKT1; MAPK1; BRAF; PIK3R1; TP53; EGFR; PIK3CG; IGF1R |
hsa04012 | ErbB signaling pathway_Homo sapiens_hsa04012 | 5.211E-12 | 9.285E-11 | CAMK2B; GSK3B; SRC; ERBB2; AKT1; MAPK1; BRAF; PIK3R1; EGFR; PTK2; PIK3CG |
hsa05219 | Bladder cancer_Homo sapiens_hsa05219 | 2.577E-12 | 5.612E-11 | DAPK1; SRC; MMP2; ERBB2; MAPK1; BRAF; MMP9; TP53; EGFR |
hsa05212 | Pancreatic cancer_Homo sapiens_hsa05212 | 7.759E-12 | 1.170E-10 | SMAD3; ERBB2; AKT1; MAPK1; BRAF; PIK3R1; TP53; EGFR; NFKB1; PIK3CG |
hsa05218 | Melanoma_Homo sapiens_hsa05218 | 1.655E-11 | 2.317E-10 | PDGFRB; AKT1; MAPK1; BRAF; PIK3R1; TP53; MET; EGFR; PIK3CG; IGF1R |
hsa04014 | Ras signaling pathway_Homo sapiens_hsa04014 | 1.141E-10 | 1.243E-09 | PDGFRB; PLA2G1B; INSR; FLT4; PIK3R1; EGFR; NFKB1; PIK3CG; IGF1R; KDR; AKT1; MAPK1; TEK; MET |
hsa04068 | FoxO signaling pathway_Homo sapiens_hsa04068 | 3.153E-11 | 3.862E-10 | PLK4; SMAD3; INSR; PLK1; AKT1; MAPK1; BRAF; PIK3R1; MAPK14; EGFR; PIK3CG; IGF1R |
hsa05213 | Endometrial cancer_Homo sapiens_hsa05213 | 2.559E-11 | 3.343E-10 | GSK3B; ERBB2; AKT1; MAPK1; BRAF; PIK3R1; TP53; EGFR; PIK3CG |
hsa05223 | Non-small cell lung cancer_Homo sapiens_hsa05223 | 5.163E-11 | 5.952E-10 | ALK; ERBB2; AKT1; MAPK1; BRAF; PIK3R1; TP53; EGFR; PIK3CG |
hsa04933 | AGE-RAGE signaling pathway in diabetic complications_Homo sapiens_hsa04933 | 5.909E-10 | 5.264E-09 | SMAD3; MMP2; PIM1; BCL2; AKT1; MAPK1; PIK3R1; MAPK14; NFKB1; PIK3CG |
hsa04722 | Neurotrophin signaling pathway_Homo sapiens_hsa04722 | 1.825E-10 | 1.788E-09 | CAMK2B; GSK3B; BCL2; AKT1; MAPK1; BRAF; PIK3R1; MAPK14; TP53; NFKB1; PIK3CG |
hsa05210 | Colorectal cancer_Homo sapiens_hsa05210 | 1.341E-10 | 1.383E-09 | GSK3B; SMAD3; BCL2; AKT1; MAPK1; BRAF; PIK3R1; TP53; PIK3CG |
hsa05161 | Hepatitis B_Homo sapiens_hsa05161 | 1.506E-09 | 1.181E-08 | SMAD3; SRC; BCL2; AKT1; MAPK1; STAT6; PIK3R1; TP53; MMP9; NFKB1; PIK3CG |
hsa04668 | TNF signaling pathway_Homo sapiens_hsa04668 | 1.378E-09 | 1.125E-08 | MMP14; MMP3; AKT1; MAPK1; MAP3K8; PIK3R1; MAPK14; MMP9; NFKB1; PIK3CG |
hsa04726 | Serotonergic synapse_Homo sapiens_hsa04726 | 1.646E-09 | 1.240E-08 | CYP2C9; APP; CYP2C8; MAOA; ALOX5; ALOX15; MAPK1; BRAF; ALOX12; CYP2C19 |
hsa05206 | MicroRNAs in cancer_Homo sapiens_hsa05206 | 3.798E-09 | 2.567E-08 | PDGFRB; DNMT1; ABCC1; ABCB1; MMP9; EGFR; NFKB1; ERBB2; PIM1; BCL2; CYP1B1; MAPK1; TP53; MET |
hsa04520 | Adherens junction_Homo sapiens_hsa04520 | 6.871E-10 | 5.855E-09 | SMAD3; CSNK2A1; SRC; INSR; ERBB2; MAPK1; MET; EGFR; IGF1R |
hsa05169 | Epstein-Barr virus infection_Homo sapiens_hsa05169 | 3.991E-09 | 2.607E-08 | GSK3B; SYK; CSNK2A1; BCL2; CDK1; AKT1; PIK3R1; MAPK14; TP53; NFKB1; PIK3CG; HSPA1A |
hsa04914 | Progesterone-mediated oocyte maturation_Homo sapiens_hsa04914 | 8.657E-09 | 5.398E-08 | PLK1; CDK1; AKT1; MAPK1; BRAF; PIK3R1; MAPK14; PIK3CG; IGF1R |
hsa05221 | Acute myeloid leukemia_Homo sapiens_hsa05221 | 1.957E-09 | 1.420E-08 | FLT3; PIM1; AKT1; MAPK1; BRAF; PIK3R1; NFKB1; PIK3CG |
hsa05160 | Hepatitis C_Homo sapiens_hsa05160 | 8.813E-09 | 5.398E-08 | GSK3B; AKT1; MAPK1; BRAF; PIK3R1; MAPK14; TP53; EGFR; NFKB1; PIK3CG |
hsa04370 | VEGF signaling pathway_Homo sapiens_hsa04370 | 3.417E-09 | 2.392E-08 | SRC; KDR; AKT1; MAPK1; PIK3R1; MAPK14; PTK2; PIK3CG |
hsa04915 | Estrogen signaling pathway_Homo sapiens_hsa04915 | 9.474E-09 | 5.627E-08 | SRC; MMP2; AKT1; MAPK1; PIK3R1; MMP9; EGFR; PIK3CG; HSPA1A |
hsa04010 | MAPK signaling pathway_Homo sapiens_hsa04010 | 5.349E-08 | 2.688E-07 | PDGFRB; DUSP3; AKT1; MAPK1; BRAF; MAP3K8; MAPT; MAPK14; TP53; EGFR; NFKB1; HSPA1A |
hsa05145 | Toxoplasmosis_Homo sapiens_hsa05145 | 4.442E-08 | 2.353E-07 | ALOX5; BCL2; AKT1; MAPK1; PIK3R1; MAPK14; NFKB1; PIK3CG; HSPA1A |
hsa04917 | Prolactin signaling pathway_Homo sapiens_hsa04917 | 1.313E-08 | 7.571E-08 | GSK3B; SRC; AKT1; MAPK1; PIK3R1; MAPK14; NFKB1; PIK3CG |
hsa05220 | Chronic myeloid leukemia_Homo sapiens_hsa05220 | 1.467E-08 | 8.218E-08 | SMAD3; AKT1; MAPK1; BRAF; PIK3R1; TP53; NFKB1; PIK3CG |
hsa04071 | Sphingolipid signaling pathway_Homo sapiens_hsa04071 | 5.142E-08 | 2.652E-07 | ABCC1; BCL2; AKT1; MAPK1; PIK3R1; MAPK14; TP53; NFKB1; PIK3CG |
hsa04062 | Chemokine signaling pathway_Homo sapiens_hsa04062 | 2.236E-07 | 1.019E-06 | GSK3B; CXCR1; SRC; AKT1; MAPK1; BRAF; PIK3R1; NFKB1; PTK2; PIK3CG |
hsa05202 | Transcriptional misregulation in cancer_Homo sapiens_hsa05202 | 1.567E-07 | 7.314E-07 | HPGD; FLT3; MMP3; TP53; MPO; MMP9; MET; NFKB1; PTK2; IGF1R |
hsa04072 | Phospholipase D signaling pathway_Homo sapiens_hsa04072 | 2.474E-07 | 1.078E-06 | PDGFRB; SYK; CXCR1; INSR; AKT1; MAPK1; PIK3R1; EGFR; PIK3CG |
hsa05203 | Viral carcinogenesis_Homo sapiens_hsa05203 | 5.226E-07 | 2.180E-06 | POLB; PKM; SYK; SRC; CDK1; MAPK1; PIK3R1; TP53; NFKB1; PIK3CG |
hsa04660 | T cell receptor signaling pathway_Homo sapiens_hsa04660 | 2.403E-07 | 1.070E-06 | GSK3B; AKT1; MAPK1; MAP3K8; PIK3R1; MAPK14; NFKB1; PIK3CG |
hsa01100 | Metabolic pathways_Homo sapiens_hsa01100 | 1.484E-06 | 5.386E-06 | DNMT1; PLA2G1B; MAOA; GAA; ALOX15; AKR1B1; ALOX12; PYGL; CYP2C19; PGD; CYP3A4; CYP19A1; HSD17B10; CYP2C9; CYP2C8; FUT7; PKM; ALOX5; HSD17B2; CYP1A2; ALDH1A1; CYP1A1; XDH |
hsa00591 | Linoleic acid metabolism_Homo sapiens_hsa00591 | 3.688E-10 | 3.442E-09 | CYP2C9; CYP2C8; PLA2G1B; CYP1A2; ALOX15; CYP3A4; CYP2C19 |
hsa04611 | Platelet activation_Homo sapiens_hsa04611 | 8.199E-07 | 3.214E-06 | SYK; SRC; AKT1; MAPK1; PIK3R1; MAPK14; PIK3CG; MYLK |
hsa04919 | Thyroid hormone signaling pathway_Homo sapiens_hsa04919 | 6.356E-07 | 2.596E-06 | GSK3B; SRC; AKT1; MAPK1; PIK3R1; TP53; HIF1A; PIK3CG |
hsa05211 | Renal cell carcinoma_Homo sapiens_hsa05211 | 1.527E-07 | 7.301E-07 | AKT1; MAPK1; BRAF; PIK3R1; MET; HIF1A; PIK3CG |
hsa04662 | B cell receptor signaling pathway_Homo sapiens_hsa04662 | 3.085E-07 | 1.314E-06 | GSK3B; SYK; AKT1; MAPK1; PIK3R1; NFKB1; PIK3CG |
hsa04913 | Ovarian steroidogenesis_Homo sapiens_hsa04913 | 2.123E-08 | 1.156E-07 | ALOX5; INSR; HSD17B2; CYP1A1; CYP1B1; CYP19A1; IGF1R |
hsa04210 | Apoptosis_Homo sapiens_hsa04210 | 2.321E-06 | 7.709E-06 | LMNA; BCL2; AKT1; MAPK1; PIK3R1; TP53; NFKB1; PIK3CG |
hsa04912 | GnRH signaling pathway_Homo sapiens_hsa04912 | 1.400E-06 | 5.258E-06 | CAMK2B; MMP14; SRC; MMP2; MAPK1; MAPK14; EGFR |
hsa05162 | Measles_Homo sapiens_hsa05162 | 1.867E-06 | 6.419E-06 | GSK3B; CSNK2A1; AKT1; PIK3R1; TP53; NFKB1; PIK3CG; HSPA1A |
hsa00590 | Arachidonic acid metabolism_Homo sapiens_hsa00590 | 9.841E-08 | 4.822E-07 | CYP2C9; CYP2C8; PLA2G1B; ALOX5; ALOX15; ALOX12; CYP2C19 |
hsa04910 | Insulin signaling pathway_Homo sapiens_hsa04910 | 2.199E-06 | 7.432E-06 | GSK3B; INSR; AKT1; MAPK1; BRAF; PIK3R1; PYGL; PIK3CG |
hsa05222 | Small cell lung cancer_Homo sapiens_hsa05222 | 9.528E-07 | 3.662E-06 | BCL2; AKT1; PIK3R1; TP53; NFKB1; PTK2; PIK3CG |
hsa04211 | Longevity regulating pathway - mammal_Homo sapiens_hsa04211 | 1.744E-06 | 6.102E-06 | INSR; AKT1; PIK3R1; TP53; NFKB1; PIK3CG; IGF1R |
hsa04550 | Signaling pathways regulating pluripotency of stem cells_Homo sapiens_hsa04550 | 2.581E-06 | 8.293E-06 | GSK3B; SMAD3; AKT1; MAPK1; PIK3R1; MAPK14; PIK3CG; IGF1R |
hsa05204 | Chemical carcinogenesis_Homo sapiens_hsa05204 | 6.879E-07 | 2.752E-06 | CYP2C9; CYP2C8; CYP1A2; CYP1A1; CYP1B1; CYP3A4; CYP2C19 |
hsa05166 | HTLV-I infection_Homo sapiens_hsa05166 | 4.164E-06 | 1.183E-05 | PDGFRB; POLB; GSK3B; SMAD3; TERT; AKT1; PIK3R1; TP53; NFKB1; PIK3CG |
hsa05231 | Choline metabolism in cancer_Homo sapiens_hsa05231 | 2.828E-06 | 8.800E-06 | PDGFRB; AKT1; MAPK1; PIK3R1; HIF1A; EGFR; PIK3CG |
hsa04810 | Regulation of actin cytoskeleton_Homo sapiens_hsa04810 | 6.665E-06 | 1.814E-05 | PDGFRB; SRC; MAPK1; BRAF; PIK3R1; PTK2; EGFR; PIK3CG; MYLK |
hsa05142 | Chagas disease (American trypanosomiasis)_Homo sapiens_hsa05142 | 3.441E-06 | 1.054E-05 | SMAD3; AKT1; MAPK1; PIK3R1; MAPK14; NFKB1; PIK3CG |
hsa04620 | Toll-like receptor signaling pathway_Homo sapiens_hsa04620 | 3.908E-06 | 1.143E-05 | AKT1; MAPK1; MAP3K8; PIK3R1; MAPK14; NFKB1; PIK3CG |
hsa04022 | cGMP-PKG signaling pathway_Homo sapiens_hsa04022 | 8.580E-06 | 2.304E-05 | INSR; AKT1; MAPK1; PIK3R1; ADRA2C; ADRA2A; PIK3CG; MYLK |
hsa04725 | Cholinergic synapse_Homo sapiens_hsa04725 | 5.312E-06 | 1.466E-05 | CAMK2B; ACHE; BCL2; AKT1; MAPK1; PIK3R1; PIK3CG |
hsa05164 | Influenza A_Homo sapiens_hsa05164 | 1.207E-05 | 3.156E-05 | GSK3B; AKT1; MAPK1; PIK3R1; MAPK14; NFKB1; PIK3CG; HSPA1A |
hsa04931 | Insulin resistance_Homo sapiens_hsa04931 | 4.707E-06 | 1.318E-05 | GSK3B; INSR; AKT1; PIK3R1; PYGL; NFKB1; PIK3CG |
hsa05152 | Tuberculosis_Homo sapiens_hsa05152 | 1.366E-05 | 3.524E-05 | CAMK2B; SYK; SRC; BCL2; AKT1; MAPK1; MAPK14; NFKB1 |
hsa04261 | Adrenergic signaling in cardiomyocytes_Homo sapiens_hsa04261 | 3.470E-05 | 8.610E-05 | CAMK2B; BCL2; AKT1; MAPK1; PIK3R1; MAPK14; PIK3CG |
hsa04921 | Oxytocin signaling pathway_Homo sapiens_hsa04921 | 5.265E-05 | 1.274E-04 | CAMK2B; SRC; MAPK1; PIK3R1; EGFR; PIK3CG; MYLK |
hsa04630 | Jak-STAT signaling pathway_Homo sapiens_hsa04630 | 5.265E-05 | 1.274E-04 | THPO; PIM1; BCL2; AKT1; STAT6; PIK3R1; PIK3CG |
hsa04150 | mTOR signaling pathway_Homo sapiens_hsa04150 | 1.741E-06 | 6.102E-06 | AKT1; MAPK1; BRAF; PIK3R1; HIF1A; PIK3CG |
hsa04380 | Osteoclast differentiation_Homo sapiens_hsa04380 | 1.659E-05 | 4.222E-05 | SYK; AKT1; MAPK1; PIK3R1; MAPK14; NFKB1; PIK3CG |
hsa04144 | Endocytosis_Homo sapiens_hsa04144 | 1.917E-04 | 4.222E-04 | SMAD3; CXCR1; SRC; KDR; MET; EGFR; HSPA1A; IGF1R |
hsa04750 | Inflammatory mediator regulation of TRP channels_Homo sapiens_hsa04750 | 3.032E-05 | 7.619E-05 | CAMK2B; SRC; ALOX12; PIK3R1; MAPK14; PIK3CG |
hsa04060 | Cytokine-cytokine receptor interaction_Homo sapiens_hsa04060 | 2.240E-04 | 4.772E-04 | PDGFRB; CXCR1; THPO; FLT3; FLT4; KDR; MET; EGFR |
hsa04213 | Longevity regulating pathway - multiple species_Homo sapiens_hsa04213 | 2.557E-06 | 8.293E-06 | INSR; AKT1; PIK3R1; PIK3CG; HSPA1A; IGF1R |
hsa04664 | Fc epsilon RI signaling pathway_Homo sapiens_hsa04664 | 3.659E-06 | 1.087E-05 | SYK; AKT1; MAPK1; PIK3R1; MAPK14; PIK3CG |
hsa04024 | cAMP signaling pathway_Homo sapiens_hsa04024 | 2.217E-04 | 4.772E-04 | CAMK2B; AKT1; MAPK1; BRAF; PIK3R1; NFKB1; PIK3CG |
hsa04114 | Oocyte meiosis_Homo sapiens_hsa04114 | 1.082E-04 | 2.465E-04 | CAMK2B; PLK1; CDK1; MAPK1; AURKA; IGF1R |
hsa04670 | Leukocyte transendothelial migration_Homo sapiens_hsa04670 | 8.597E-05 | 2.030E-04 | MMP2; PIK3R1; MAPK14; MMP9; PTK2; PIK3CG |
hsa04932 | Non-alcoholic fatty liver disease (NAFLD)_Homo sapiens_hsa04932 | 3.300E-04 | 6.881E-04 | GSK3B; INSR; AKT1; PIK3R1; NFKB1; PIK3CG |
hsa04728 | Dopaminergic synapse_Homo sapiens_hsa04728 | 1.405E-04 | 3.130E-04 | CAMK2B; GSK3B; MAOA; AKT1; MAPK14; DRD4 |
hsa05010 | Alzheimer's disease_Homo sapiens_hsa05010 | 5.815E-04 | 1.175E-03 | BACE1; APP; GSK3B; MAPK1; MAPT; HSD17B10 |
hsa00140 | Steroid hormone biosynthesis_Homo sapiens_hsa00140 | 1.422E-06 | 5.258E-06 | CYP1A2; HSD17B2; CYP1A1; CYP1B1; CYP3A4; CYP19A1 |
hsa04080 | Neuroactive ligand-receptor interaction_Homo sapiens_hsa04080 | 2.752E-02 | 4.150E-02 | GPR35; NMUR2; ADRA2C; ADRA2A; DRD4 |
hsa04020 | Calcium signaling pathway_Homo sapiens_hsa04020 | 4.962E-03 | 8.606E-03 | PDGFRB; CAMK2B; ERBB2; EGFR; MYLK |
hsa05168 | Herpes simplex infection_Homo sapiens_hsa05168 | 2.679E-02 | 4.070E-02 | CSNK2A1; CDK1; TP53; NFKB1 |
hsa04310 | Wnt signaling pathway_Homo sapiens_hsa04310 | 1.792E-03 | 3.346E-03 | CAMK2B; GSK3B; SMAD3; CSNK2A1; TP53 |
hsa04650 | Natural killer cell mediated cytotoxicity_Homo sapiens_hsa04650 | 1.434E-03 | 2.703E-03 | SYK; MAPK1; BRAF; PIK3R1; PIK3CG |
hsa00830 | Retinol metabolism_Homo sapiens_hsa00830 | 2.803E-06 | 8.800E-06 | CYP2C9; CYP2C8; CYP1A2; ALDH1A1; CYP1A1; CYP3A4 |
hsa05120 | Epithelial cell signaling in Helicobacter pylori infection_Homo sapiens_hsa05120 | 3.659E-06 | 1.087E-05 | CXCR1; SRC; MAPK14; MET; EGFR; NFKB1 |
hsa04152 | AMPK signaling pathway_Homo sapiens_hsa04152 | 9.822E-04 | 1.887E-03 | INSR; AKT1; PIK3R1; PIK3CG; IGF1R |
hsa04110 | Cell cycle_Homo sapiens_hsa04110 | 9.822E-04 | 1.887E-03 | GSK3B; SMAD3; PLK1; CDK1; TP53 |
hsa04360 | Axon guidance_Homo sapiens_hsa04360 | 1.093E-03 | 2.080E-03 | GSK3B; MAPK1; MET; PTK2; EPHB4 |
hsa04916 | Melanogenesis_Homo sapiens_hsa04916 | 2.334E-02 | 3.601E-02 | CAMK2B; GSK3B; MAPK1 |
hsa04666 | Fc gamma R-mediated phagocytosis_Homo sapiens_hsa04666 | 2.634E-04 | 5.551E-04 | SYK; AKT1; MAPK1; PIK3R1; PIK3CG |
hsa04270 | Vascular smooth muscle contraction_Homo sapiens_hsa04270 | 6.286E-03 | 1.062E-02 | PLA2G1B; MAPK1; BRAF; MYLK |
hsa04922 | Glucagon signaling pathway_Homo sapiens_hsa04922 | 3.413E-03 | 6.026E-03 | CAMK2B; PKM; AKT1; PYGL |
hsa00982 | Drug metabolism - cytochrome P450_Homo sapiens_hsa00982 | 3.987E-06 | 1.149E-05 | CYP2C9; CYP2C8; MAOA; CYP1A2; CYP3A4; CYP2C19 |
hsa05146 | Amoebiasis_Homo sapiens_hsa05146 | 3.293E-03 | 5.867E-03 | PIK3R1; NFKB1; PTK2; PIK3CG |
hsa04540 | Gap junction_Homo sapiens_hsa04540 | 2.034E-04 | 4.430E-04 | PDGFRB; SRC; CDK1; MAPK1; EGFR |
hsa04064 | NF-kappa B signaling pathway_Homo sapiens_hsa04064 | 2.533E-03 | 4.597E-03 | SYK; CSNK2A1; BCL2; NFKB1 |
hsa05100 | Bacterial invasion of epithelial cells_Homo sapiens_hsa05100 | 1.151E-04 | 2.592E-04 | SRC; PIK3R1; MET; PTK2; PIK3CG |
hsa00980 | Metabolism of xenobiotics by cytochrome P450_Homo sapiens_hsa00980 | 8.388E-05 | 2.005E-04 | CYP2C9; CYP1A2; CYP1A1; CYP1B1; CYP3A4 |
hsa05132 | Salmonella infection_Homo sapiens_hsa05132 | 1.903E-03 | 3.520E-03 | MAPK1; PKN1; MAPK14; NFKB1 |
hsa05140 | Leishmaniasis_Homo sapiens_hsa05140 | 1.010E-02 | 1.650E-02 | MAPK1; MAPK14; NFKB1 |
hsa04971 | Gastric acid secretion_Homo sapiens_hsa04971 | 1.048E-02 | 1.698E-02 | CAMK2B; CA2; MYLK |
hsa05133 | Pertussis_Homo sapiens_hsa05133 | 1.087E-02 | 1.746E-02 | MAPK1; MAPK14; NFKB1 |
hsa04976 | Bile secretion_Homo sapiens_hsa04976 | 9.342E-04 | 1.831E-03 | ABCB1; CA2; CYP3A4; ABCG2 |
hsa04720 | Long-term potentiation_Homo sapiens_hsa04720 | 7.663E-03 | 1.273E-02 | CAMK2B; MAPK1; BRAF |
hsa04730 | Long-term depression_Homo sapiens_hsa04730 | 5.884E-03 | 1.003E-02 | MAPK1; BRAF; IGF1R |
hsa05321 | Inflammatory bowel disease (IBD)_Homo sapiens_hsa05321 | 7.347E-03 | 1.231E-02 | SMAD3; STAT6; NFKB1 |
hsa05131 | Shigellosis_Homo sapiens_hsa05131 | 6.695E-04 | 1.339E-03 | SRC; MAPK1; MAPK14; NFKB1 |
hsa04923 | Regulation of lipolysis in adipocytes_Homo sapiens_hsa04923 | 3.788E-04 | 7.735E-04 | INSR; AKT1; PIK3R1; PIK3CG |
hsa04621 | NOD-like receptor signaling pathway_Homo sapiens_hsa04621 | 5.098E-03 | 8.765E-03 | MAPK1; MAPK14; NFKB1 |
hsa00983 | Drug metabolism - other enzymes_Homo sapiens_hsa00983 | 3.208E-02 | 4.800E-02 | CYP3A4; XDH |
hsa05014 | Amyotrophic lateral sclerosis (ALS)_Homo sapiens_hsa05014 | 3.726E-03 | 6.520E-03 | BCL2; MAPK14; TP53 |
hsa04930 | Type II diabetes mellitus_Homo sapiens_hsa04930 | 1.080E-05 | 2.860E-05 | PKM; INSR; MAPK1; PIK3R1; PIK3CG |
hsa04973 | Carbohydrate digestion and absorption_Homo sapiens_hsa04973 | 2.607E-03 | 4.688E-03 | AKT1; PIK3R1; PIK3CG |
hsa00620 | Pyruvate metabolism_Homo sapiens_hsa00620 | 2.475E-02 | 3.790E-02 | PKM; GLO1 |
hsa05020 | Prion diseases_Homo sapiens_hsa05020 | 1.926E-02 | 2.996E-02 | MAPK1; HSPA1A |
hsa02010 | ABC transporters_Homo sapiens_hsa02010 | 2.444E-03 | 4.477E-03 | ABCC1; ABCB1; ABCG2 |
hsa04960 | Aldosterone-regulated sodium reabsorption_Homo sapiens_hsa04960 | 9.189E-05 | 2.144E-04 | INSR; MAPK1; PIK3R1; PIK3CG |
hsa00052 | Galactose metabolism_Homo sapiens_hsa00052 | 1.436E-02 | 2.270E-02 | GAA; AKR1B1 |
hsa03410 | Base excision repair_Homo sapiens_hsa03410 | 1.722E-02 | 2.701E-02 | POLB; APEX1 |
hsa04320 | Dorso-ventral axis formation_Homo sapiens_hsa04320 | 1.173E-02 | 1.868E-02 | MAPK1; EGFR |
hsa00380 | Tryptophan metabolism_Homo sapiens_hsa00380 | 1.016E-04 | 2.343E-04 | MAOA; CYP1A2; CYP1A1; CYP1B1 |
hsa05216 | Thyroid cancer_Homo sapiens_hsa05216 | 7.207E-04 | 1.427E-03 | MAPK1; BRAF; TP53 |
hsa04964 | Proximal tubule bicarbonate reclamation_Homo sapiens_hsa04964 | 8.587E-03 | 1.414E-02 | CA2; CA4 |
hsa00232 | Caffeine metabolism_Homo sapiens_hsa00232 | 3.647E-04 | 7.523E-04 | CYP1A2; XDH |
ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
---|---|---|---|
G00-G99: Diseases of the nervous system G00-G99 | Multiple scierosis | G35 | MPO |
G00-G99: Diseases of the nervous system G00-G99 | Encephalopathy | G93.4 | XDH |
I00-I99: Diseases of the circulatory system | Cerebrovascular ischaemia | I61-I63 | EGFR |
I00-I99: Diseases of the circulatory system | Cerebral amyloid angiopathy | I68.0 | APP |
G00-G99: Diseases of the nervous system G00-G99 | Central nervous system disease | G00-G99 | MAPT |
C00-D49: Neoplasms | Acute lymphoblastic leukemia | C91.0 | FLT3 |
C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | TERT; FLT3; FLT3; DNMT1; DNMT1; AURKB; AURKA; TP53; TP53; PLK1 |
J00-J99: Diseases of the respiratory system | Acute lung injury | J80 | MAPK14 |
I00-I99: Diseases of the circulatory system | Coronary artery disease | I20-I25 | MAPK14; MAPK14 |
I00-I99: Diseases of the circulatory system | Myocardial infarction | I21, I22 | PIK3CG; MMP3 |
G00-G99: Diseases of the nervous system G00-G99 | Motor neurone disease | G12.2 | IGF1R |
C00-D49: Neoplasms | Clear cell renal cell carcinoma | C64 | CA9 |
C00-D49: Neoplasms | CLL | NA | FLT3 |
C00-D49: Neoplasms | Advanced breast cancer | C50 | SRC; CYP19A1 |
NA: NA | Acute respiratory distress syndrome | NA | MAPK14 |
C00-D49: Neoplasms | Adrenocortical carcinoma | C74.0 | ABCB1 |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoarthritis | M15-M19, M47 | ALOX5; MMP13; MMP3; MMP2 |
A00-B99: Certain infectious and parasitic diseases | Infections disease | A00-B99 | MPO |
C00-D49: Neoplasms | Prostate cancer | C61 | TERT; PIK3CG; FLT3; FLT4; EGFR; ERBB2; BCL2; PLK1 |
N00-N99: Diseases of the genitourinary system | Prostate disease | N42.9 | CYP19A1 |
S00-T88: Injury, poisoning and certain other consequences of external causes | Allergy | T78.4 | PLA2G1B; ALOX5; SYK |
C00-D49: Neoplasms | Chronic myelogenous leukaemia | C92.1 | SRC |
C00-D49: Neoplasms | Advanced renal cell carcinoma | C64 | KDR; KDR |
C00-D49: Neoplasms | Advanced malignancies | C00-C96 | KDR |
C00-D49: Neoplasms | Advanced melanoma | C43 | BCL2 |
E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricemia | E79.0 | XDH |
I00-I99: Diseases of the circulatory system | Hypotension | I95 | ADRA2C |
H00-H59: Diseases of the eye and adnexa | Corneal ulcers | H16.0 | MMP3 |
S00-T88: Injury, poisoning and certain other consequences of external causes | Contusion | S36.220S | ADRA2C |
C00-D49: Neoplasms | Fallopian tube cancer | C57.0, D28.2 | KDR |
C00-D49: Neoplasms | Thyroid cancer | C73 | BRAF; KDR |
I00-I99: Diseases of the circulatory system | Thrombosis | I80-I82 | ALOX5; SYK |
C00-D49: Neoplasms | Colorectal cancer | C18-C21 | FLT3; IGF1R; MMP9; EGFR; EGFR; ERBB2; TP53; KDR |
L00-L99: Diseases of the skin and subcutaneous tissue | Contact dermatitis | L23, L24, L25 | PLA2G1B |
A00-B99: Certain infectious and parasitic diseases | Fungal infections | B35-B49 | ALOX5 |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Fibromyalgia | M79.7 | ADRA2C |
C00-D49: Neoplasms | Gastric cancer | C16 | EGFR; EGFR; ERBB2; KDR; KDR |
C00-D49: Neoplasms | Hormonally-responsive breast cancer | C50 | CYP19A1 |
C00-D49: Neoplasms | Non-hodgkin's lymphoma | C85 | SYK; PIK3CG; PIK3CG; ERBB2; PLK1 |
C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | MET; ABCB1; DNMT1; IGF1R; IGF1R; PDGFRB; EGFR; EGFR; AXL; KDR |
C00-D49: Neoplasms | Gliosarcoma | NA | FLT3 |
C00-D49: Neoplasms | Lung cancer | C33-C34 | MMP2; FLT4; EGFR |
E00-E89: Endocrine, nutritional and metabolic diseases | Hypoglycemia | E16.0-E16.2 | INSR |
C00-D49: Neoplasms | Colon cancer | C50 | FLT3; EGFR |
C00-D49: Neoplasms | Oral cavity cancer | C00-C08 | TP53 |
C00-D49: Neoplasms | Myeloid leukemia | C92 | FLT3 |
G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis diagnosis | G70.0 | ACHE |
A00-B99: Certain infectious and parasitic diseases | Visceral leishmaniasis | B55.0 | PLA2G1B |
C00-D49: Neoplasms | Advanced cancers | C00-C96 | EGFR |
I00-I99: Diseases of the circulatory system | Stroke | I61-I63, I80-I82 | MMP9 |
I00-I99: Diseases of the circulatory system | Atherosclerosis | I70 | ALOX5 |
J00-J99: Diseases of the respiratory system | Asthma | J45 | PLA2G1B; ALOX5; ALOX5; SYK; SYK; ERBB2; ADRA2C |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | PLA2G1B; ABCC1; ALOX5; PIK3CG; TEK; MAPK14 |
I00-I99: Diseases of the circulatory system | Arteriosclerosis | I70 | PLA2G1B |
L00-L99: Diseases of the skin and subcutaneous tissue | Fibrosis | L90.5 | MET |
C00-D49: Neoplasms | Ocular cancer | C69 | APEX1 |
H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | ADRA2C; CA4; CA4 |
H00-H59: Diseases of the eye and adnexa | Ocular disease | H00-H59 | ADRA2C |
H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | ACHE; CA4; CA2 |
H00-H59: Diseases of the eye and adnexa | Ocular inflammation | H16.229 | TERT |
I00-I99: Diseases of the circulatory system | Pulmonary arterial hypertension | I27.0, I27.2 | HIF1A |
S00-T88: Injury, poisoning and certain other consequences of external causes | Vascular restinosis following vascular graft surgery | T82.858A | FLT4 |
E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricaemia in gout | E79.0, M10 | XDH |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Attention deficit hyperactivity disorder | F90 | ADRA2A |
A00-B99: Certain infectious and parasitic diseases | Bacterial infections | A00-B99 | ABCB1; PIK3CG; CYP2C9 |
A00-B99: Certain infectious and parasitic diseases | Pediculus humanus capitis | B85.0 | ACHE |
K00-K95: Diseases of the digestive system | Peptic ulcer | K25-K27 | ADRA2C |
G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | PKM; MMP13; ACHE; IGF1R; INSR; CDK1; ADRA2C; ADRA2A |
L00-L99: Diseases of the skin and subcutaneous tissue | Vitiligo | L80 | MAOA |
I00-I99: Diseases of the circulatory system | Heart disease | I00-I52 | MET |
N00-N99: Diseases of the genitourinary system | Urinary dysfunction | N39.3-N39.4 | ACHE |
K00-K95: Diseases of the digestive system | Ulcerative colitis | K51 | MMP9 |
NA: NA | Upper abdominal bloating | NA | ACHE |
C00-D49: Neoplasms | Urethral cancer | NA | EGFR |
J00-J99: Diseases of the respiratory system | Allergic rhinitis | J00, J30, J31.0, T78.4 | PLA2G1B; ADRA2C |
E00-E89: Endocrine, nutritional and metabolic diseases | Autoimmune diabetes | E08-E13 | SYK; INSR |
L00-L99: Diseases of the skin and subcutaneous tissue | Atopic dermatitis | L00-L99 | ALOX5 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Erectile dysfunction | F52.2, N48.4 | DRD4 |
I00-I99: Diseases of the circulatory system | Hypertension | I10-I16 | ADRA2C |
E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | INSR |
C00-D49: Neoplasms | Ovarian cancer | C56 | TERT; ABCB1; MMP2; EGFR; EGFR; KDR; KDR; KDR; KDR |
C00-D49: Neoplasms | Osteosarcoma | C40-C41 | GSK3B; SRC |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis | M80-M81, Z79.890 | SRC |
E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | PIK3CG; PIK3CG; INSR; NFKB1 |
E00-E89: Endocrine, nutritional and metabolic diseases | Type 1/2 diabetes | E08-E13 | INSR |
C00-D49: Neoplasms | Tumors | C00-D48 | TERT |
S00-T88: Injury, poisoning and certain other consequences of external causes | Toxicity | T36-T50, T51-T65 | TP53 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | MAPT; ACHE |
A00-B99: Certain infectious and parasitic diseases | Human immunodeficiency virus infection | B20-B26 | FLT3 |
E00-E89: Endocrine, nutritional and metabolic diseases | Hunter syndrome | E76.1 | INSR |
E00-E89: Endocrine, nutritional and metabolic diseases | Hyperglycaemia in type 2 diabetes | E11, R73.9 | INSR |
E00-E89: Endocrine, nutritional and metabolic diseases | Hypercholesterolemia | E78 | INSR |
C00-D49: Neoplasms | Liver cancer | C22 | TERT; IGF1R; KDR |
A00-B99: Certain infectious and parasitic diseases | Leishmaniasis | B55.0 | PLA2G1B |
C00-D49: Neoplasms | Leukemia | C90-C95 | AKT1; FLT3; BCL2 |
C00-D49: Neoplasms | Late-stage solid tumors | C00-C75, C7A, C7B, D10-D36, D3A | DNMT1; PTK2; BRAF; AURKA; TP53 |
S00-T88: Injury, poisoning and certain other consequences of external causes | Myocardial reperfusion injury | T86.4 | AKT1 |
S00-T88: Injury, poisoning and certain other consequences of external causes | Nerve injury | T14.4 | PLA2G1B |
NA: NA | Hematopoietic stem cell transplantation | NA | FLT3 |
L00-L99: Diseases of the skin and subcutaneous tissue | Pruritus | L29 | PLA2G1B; ALOX5 |
L00-L99: Diseases of the skin and subcutaneous tissue | Psoriasis | L40 | ALOX5; FLT3; MAPK14; EGFR; BCL2 |
I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2 |
E00-E89: Endocrine, nutritional and metabolic diseases | Hormone deficiency | E00-E90 | IGF1R |
H00-H59: Diseases of the eye and adnexa | Macular degeneration | H35.3 | APP |
C00-D49: Neoplasms | Lymphoma | C81-C86 | AKT1; PIK3CG; PIK3CG; CA9; INSR; HIF1A; EGFR; ERBB2; BCL2; PLK1 |
K00-K95: Diseases of the digestive system | Liver disease | K70-K77 | MET |
C00-D49: Neoplasms | Locally advanced head and neck cancer | C07-C14, C32, C33 | EGFR |
A00-B99: Certain infectious and parasitic diseases | Lymphatic filariasis | B74 | ALOX5 |
NA: NA | Anaplastic mixed oligoastrocytoma | NA | FLT3 |
E00-E89: Endocrine, nutritional and metabolic diseases | Amyloidosis | E85 | APP |
C00-D49: Neoplasms | Myelofibrosis | C94.4, D47.4 | FLT3 |
C00-D49: Neoplasms | Myelodysplastic syndrome | D46 | DNMT1; DNMT1; TEK; KDR |
C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | MPO; PLA2G1B; ALOX5; MMP13; SYK; PIK3CG; MAPK14 |
NA: NA | Inflammatory diseases | NA | MAPK14 |
L00-L99: Diseases of the skin and subcutaneous tissue | Psoriatic disorder | L40 | IGF1R |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Psychotic disorders | F20-F29 | DRD4 |
C00-D49: Neoplasms | Hematological malignancies | C81-C86 | SYK; SRC; AURKB; TP53 |
C00-D49: Neoplasms | Hematologic malignancies | C81-C86 | AKT1; PIK3CG |
A00-B99: Certain infectious and parasitic diseases | Helminth infection | A00-B99 | ACHE |
C00-D49: Neoplasms | HER2-positive urogenital cancer | NA | ERBB2 |
C00-D49: Neoplasms | Hepatocellular carcinoma | C22.0 | MET; IGF1R; FLT4; KDR |
C00-D49: Neoplasms | Inflammatory breast cancer | C50 | EGFR |
E00-E89: Endocrine, nutritional and metabolic diseases | Inflammation | E08-E13, E10.2, E11, E11.2, E13.2, I73.9, I80-I82, N00-N29, G89 | ALOX5 |
L00-L99: Diseases of the skin and subcutaneous tissue | Inflammatory and pruritic manifestations of corticosteroid responsive dermatoses | L20-L30 | PLA2G1B |
L00-L99: Diseases of the skin and subcutaneous tissue | Inflammatory and pruritic manifestations of moderate to severe corticosteroid-responsive dermatoses of the scalp | L20-L30 | PLA2G1B |
K00-K95: Diseases of the digestive system | Inflammatory bowel disease | K50, K51 | MAPK14 |
E00-E89: Endocrine, nutritional and metabolic diseases | Obesity | E66 | ADRA2C |
E00-E89: Endocrine, nutritional and metabolic diseases | Non-insulin dependent diabetes | E11.9 | INSR |
C00-D49: Neoplasms | Non-small-cell lung cancer | NA | MMP2; KDR |
C00-D49: Neoplasms | Refractory renal cell carcinoma | C64 | PKM |
G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | MAPT; ACHE |
I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | ADRA2C; NPSR1; APP |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CA2 |
K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA1; MYLK; CA2 |
I00-I99: Diseases of the circulatory system | Acute coronary syndrome | I74 | MAPK14 |
C00-D49: Neoplasms | Head and neck squamous cell carcinoma | C44 | EGFR |
A00-B99: Certain infectious and parasitic diseases | HCV infection | B17.1, B18.2 | MMP3 |
C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | AKR1B1; TERT; EGFR; EGFR; EGFR; TP53; KDR; KDR |
H60-H95: Diseases of the ear and mastoid process | Hearing disorder | H90.5 | TP53 |
I00-I99: Diseases of the circulatory system | Heart failure | I50 | XDH; ADRA2C |
I00-I99: Diseases of the circulatory system | Ischemia | I99.8 | SRC; TEK |
G00-G99: Diseases of the nervous system G00-G99 | Neuropathic pain | G64, G90.0 | MAOA |
I00-I99: Diseases of the circulatory system | Restenosis | I51.89 | MAPK1 |
J00-J99: Diseases of the respiratory system | Respiratory disease | J00-J99 | ALOX5 |
C00-D49: Neoplasms | Renal cell carcinoma | NA | MMP2; KDR; KDR |
C00-D49: Neoplasms | Renal cancer | C64 | CA9; KDR |
I00-I99: Diseases of the circulatory system | Renal artery disease | I70.1 | TP53 |
C00-D49: Neoplasms | Refractory breast cancer | C50 | EGFR |
NA: NA | Angioedema | NA | PIK3CG |
K00-K95: Diseases of the digestive system | Xerostomia | K11.7, R68.2 | ACHE |
S00-T88: Injury, poisoning and certain other consequences of external causes | Vulnerary | S00-T98 | EGFR |
N00-N99: Diseases of the genitourinary system | Endometriosis | N80 | CYP19A1 |
C00-D49: Neoplasms | Endometrial cancer | C54.1 | PIK3CG; PIK3CG |
NA: NA | Edema | NA | CA2 |
I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Major depressive disorder | F32, F33, M32 | MAOA; MAOA |
C00-D49: Neoplasms | Haematological malignancies | C81-C86 | AURKA |
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Growth failure | R62.8 | IGF1R |
H00-H59: Diseases of the eye and adnexa | Graves' ophthalmopathy | H06.2 | IGF1R |
C00-D49: Neoplasms | Mesothelioma | C45 | PTK2 |
C00-D49: Neoplasms | Metastasis | C00-C97 | AXL |
C00-D49: Neoplasms | Metastatic breast cancer | C50 | PIK3CG; KDR |
C00-D49: Neoplasms | Metastatic castration-resistant prostate cancer | C61 | KDR |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | CAMK2B; AKR1B1; PLA2G1B; ALOX5; SYK; MMP3; MAPK14 |
H00-H59: Diseases of the eye and adnexa | Retinal venous occlusion | H34.8 | ERBB2 |
NA: NA | Rheumatold arthritis | NA | MAPK14 |
J00-J99: Diseases of the respiratory system | Rhinitis | J00, J30, J31.0 | ALOX5 |
L00-L99: Diseases of the skin and subcutaneous tissue | Erythema | L51-L54 | ADRA2C |
NA: NA | Enthesopathy | NA | PIK3CG |
G00-G99: Diseases of the nervous system G00-G99 | Epilepsy | G40 | MAOA |
G00-G99: Diseases of the nervous system G00-G99 | Epileptic seizures | G40, P90, R56 | ACHE |
C00-D49: Neoplasms | Esophageal cancer | C15 | EGFR |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | AKR1B1; ABCC1; ABCC1; XDH |
NA: NA | Geographic retinal atrophy | NA | APP |
NA: NA | GIST | NA | FLT3 |
H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | AKR1B1; CA1; CA1; ACHE; ADRA2C |
C00-D49: Neoplasms | Glioblastoma | NA | FLT3 |
C00-D49: Neoplasms | Glioblastoma multiforme | C71 | DNMT1; SRC; EGFR; EGFR; ERBB2 |
C00-D49: Neoplasms | Glioma | C71 | PIK3CG; EGFR; EGFR; KDR; APP |
G00-G99: Diseases of the nervous system G00-G99 | Mild to moderate alzheimer disease | G30 | APP |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mild cognitive impairment | F06.7 | ACHE; APP |
C00-D49: Neoplasms | Metastatic HER2-negative gastric cancer | NA | MET |
C00-D49: Neoplasms | Metastatic colorectal cancer | C18-C21 | EGFR; KDR |
C00-D49: Neoplasms | Metastatic melanoma | C43 | BRAF; BRAF |
NA: NA | Early satiation associated with functional dyspepsia | NA | ACHE |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Schizophrenia | F20 | DRD4 |
L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | MMP2 |
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Chronic pain | R52.1-R52.2, G89 | ERBB2 |
S00-T88: Injury, poisoning and certain other consequences of external causes | Poison intoxication | T36-T50 | ACHE; ADRA2C |
K00-K95: Diseases of the digestive system | Gastrointestinal disease | K00-K93 | EGFR |
C00-D49: Neoplasms | Gastrointestinal cancers | C15-C26 | ERBB2; KDR |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Male sexual disorders | F52 | ADRA2C |
C00-D49: Neoplasms | Malignant adrenal gland cancer | C74.0 | IGF1R |
C00-D49: Neoplasms | Multiple myeloma | C90 | TERT; SRC; IGF1R; BCL2 |
C00-D49: Neoplasms | Late-stage non-small cell lung cancer | C33-C34 | EPHB4 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Sexual dysfunction | F52 | ADRA2A |
C00-D49: Neoplasms | Breast cancer | C50 | TERT; PIK3CG; FLT3; FLT3; CA9; IGF1R; INSR; CYP19A1; CDK1; EGFR; EGFR; EGFR; ERBB2; ERBB2; ERBB2; BCL2; KDR; KDR; KDR |
S00-T88: Injury, poisoning and certain other consequences of external causes | Brain injury | S09.90 | PDGFRB; APP |
C00-D49: Neoplasms | Brain cancer | C71, D33 | TERT; SRC; EGFR; EGFR |
J00-J99: Diseases of the respiratory system | Airway inflammation | J00-J99 | FLT3 |
H00-H59: Diseases of the eye and adnexa | Age related macular degeneration | H35.3 | APP |
C00-D49: Neoplasms | Advanced solid tumor | C00-C75, C7A, C7B | MET; PIK3CG; PIK3CG; AURKA; PLK1 |
C00-D49: Neoplasms | Cutaneous Melanoma | C43-C44 | KDR |
A00-B99: Certain infectious and parasitic diseases | Cryptosporidium infection | A07.2 | EGFR |
C00-D49: Neoplasms | Pancreatic cancer | C25 | AKT1; TERT; FLT3; MMP2; EGFR; KDR; PLK1 |
G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | MPO; MAOA; ACHE; BRAF |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Alcohol use disorders | F10.2 | MAOA; ADRA2C |
C00-D49: Neoplasms | Melanoma | C43 | TERT; BRAF; EGFR; KDR; KDR |
C00-D49: Neoplasms | Solid tumors | NA | BRAF |
C00-D49: Neoplasms | Soft tissue sarcoma | C00-D49 | DNMT1 |
C00-D49: Neoplasms | Solid tumours | C00-D48 | AKT1; MET; PKM; ABCB1; SYK; PIK3CG; FLT3; CA9; MMP2; MMP14; SRC; IGF1R; PTK2; AURKB; AURKA; FLT4; TEK; PDGFRB; HIF1A; MAPK1; MMP9; EGFR; ERBB2; TP53; KDR; KDR; KDR; PLK1; PLK1; TOP2A |
C00-D49: Neoplasms | Squamous cell cancer of head and neck | NA | KDR |
C00-D49: Neoplasms | B-cell lymphoma | C85.1 | SYK |
D50-D89: Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism | Beta thalassemia | D56.1 | HBB |
C00-D49: Neoplasms | Biliary cancer | C22, C24 | KDR |
C00-D49: Neoplasms | Bladder cancer | C67 | CYP19A1; EGFR; ERBB2 |
C00-D49: Neoplasms | AML | NA | FLT3; KDR |
G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | MAOA; GSK3B; MAPT; ACHE; ACHE; ACHE; INSR; ADRA2C; APP |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | AKR1B1; GSK3B; PDGFRB; INSR |
L00-L99: Diseases of the skin and subcutaneous tissue | Dermatitis | L20-L30 | ALOX5 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Depression | F30-F39 | MAOA; ADRA2C |
K00-K95: Diseases of the digestive system | Crohn's disease | K50 | INSR |
E00-E89: Endocrine, nutritional and metabolic diseases | Type 1 diabetes | E10 | INSR |
E00-E89: Endocrine, nutritional and metabolic diseases | Pompe's disease | E74.02 | GAA |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic nephropathy | E11.21 | ADRA2C |
G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis | G70.0 | ACHE |
I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | PIK3CG; KDR |
G00-G99: Diseases of the nervous system G00-G99 | Amyotrophic lateral sclerosis | G12.2 | BCL2 |
G00-G99: Diseases of the nervous system G00-G99 | Diagnostic imaging | G30, I73.9 | APP |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic cataract | E10.36, E11.36 | AKR1B1 |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic complication | E08-E13 | AKR1B1 |
L00-L99: Diseases of the skin and subcutaneous tissue | Diabetic foot ulcer | L88-L89 | EGFR |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic neuropathy | E11.40 | AKR1B1 |
H00-H59: Diseases of the eye and adnexa | Diabetic retinopathy | H36, E10.3, E11.3, E13.3 | MAPK14 |
I00-I99: Diseases of the circulatory system | Ischemic stroke | I61-I63 | MMP3 |
K00-K95: Diseases of the digestive system | Chemotherapy-induced mucositis | K12.3 | MET |
H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | CA1; ACHE |
C00-D49: Neoplasms | Peritoneal cavity cancer | NA | KDR |
S00-T88: Injury, poisoning and certain other consequences of external causes | Poisoning due to pesticides and chemicals | T36-T50 | ACHE |
C00-D49: Neoplasms | Cancer | C00-C96 | AKT1; MET; GSK3B; CSNK2A1; ABCB1; SYK; PIK3CG; CA1; FLT3; FLT3; CA9; MMP2; ACHE; DNMT1; SRC; IGF1R; PTK2; BRAF; BRAF; AURKA; FLT4; EPHB4; TEK; HIF1A; CDK1; MAPK1; MAPK14; MMP9; NFKB1; EGFR; ERBB2; ERBB2; PIM1; BCL2; BCL2; TP53; KDR; PLK1; APP |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | CAMK2B; MAOA; ACHE; CYP3A4 |
I00-I99: Diseases of the circulatory system | Angiogenesis disorder | I00-I99 | KDR |
C00-D49: Neoplasms | Diffuse large B-cell lymphoma | C83.3 | PIK3CG |
C00-D49: Neoplasms | Malignant tumor | C00-C75, C7A, C7B | EGFR |
C00-D49: Neoplasms | Medullary thyroid cancer | C73 | KDR |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mood disorder | F30-F39 | MAOA |
C00-D49: Neoplasms | Chronic lymphocytic leukaemia | C91 | SYK; EGFR; BCL2 |
J00-J99: Diseases of the respiratory system | Chronic obstructive pulmonary disease | J40-J44, J47 | MPO; ALOX5; MAPK14 |